Koninklijke Philips N.V. (RYLPF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Koninklijke Philips N.V. (RYLPF) trades at $25.99 with AI Score 44/100 (Grade C). Koninklijke Philips N. V. is a global health technology company focused on diagnostic and treatment solutions, connected care, and personal health products. Market cap: $25.24B, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for RYLPF: RYLPF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RYLPF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
RYLPF: the 1 perspectives are evenly split.
How is this calculated? →Koninklijke Philips N.V. (RYLPF) Healthcare & Pipeline Overview
Koninklijke Philips N.V. is a diversified health technology company providing diagnostic imaging, connected care, and personal health solutions worldwide. With a history dating back to 1891, Philips leverages its brand recognition and technological expertise to address evolving healthcare needs and consumer preferences, operating with a market cap of $25.24B.
What Is the Investment Thesis for RYLPF?
Koninklijke Philips N.V. presents a compelling investment case based on its strategic focus on health technology and its diversified portfolio of products and services. The company's established market position in diagnostic imaging and connected care, combined with its growing presence in personal health, provides multiple avenues for growth. With a market capitalization of $25.24B and a dividend yield of 3.48%, Philips offers a blend of value and income potential. Key catalysts include ongoing collaborations to enhance AI-driven diagnostic capabilities and expansion into emerging markets. Potential risks include regulatory hurdles and competition from established players like JDHIF and KONEF.
Based on FMP financials and quantitative analysis
RYLPF Key Highlights
- Market Cap of $25.24B reflects its significant presence in the health technology sector.
- P/E ratio of 25.94 indicates investor expectations for future earnings growth.
- Gross Margin of 45.2% demonstrates its ability to maintain profitability across its product lines.
- Dividend Yield of 3.48% provides a steady income stream for investors.
- Beta of 0.94 suggests lower volatility compared to the overall market.
Who Are RYLPF's Competitors?
RYLPF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| JDHIF JD Health International Inc. | $5.85 | +0.00% | $18.66B | 51 |
| OTSKF Otsuka Holdings Co., Ltd. | $64.00 | -3.03% | $33.67B | 58 |
| OTSKY Otsuka Holdings Co., Ltd. | $36.05 | -0.21% | $38.01B | 58 |
| SDMHF Sartorius Stedim Biotech S.A. | $205.60 | -4.09% | $20.00B | — |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| DNAY Codex DNA, Inc. | $1.30 | +8.33% | $38.32M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RYLPF's Key Strengths?
- Strong brand reputation in healthcare technology.
- Diversified product portfolio across diagnosis, treatment, and personal health.
- Global presence and established distribution network.
- Focus on innovation and strategic partnerships.
What Are RYLPF's Weaknesses?
- Exposure to regulatory risks and healthcare policy changes.
- Dependence on hospital capital spending cycles.
- Product recalls and safety concerns.
- OTC market trading may limit liquidity.
What Could Drive RYLPF Stock Higher?
- Strategic collaborations with Ibex Medical Analytics and NICO.LAB to enhance AI-driven diagnostic capabilities.
- Expansion into emerging markets with increasing healthcare spending.
- Development and launch of new personal health products to meet consumer demand.
- Focus on sustainability and social responsibility initiatives to enhance brand reputation.
- Potential regulatory approvals for new medical devices and technologies.
What Are the Key Risks for RYLPF?
- Regulatory hurdles and healthcare policy changes could impact the company's operations and profitability.
- Intense competition from established medical device companies and disruptive innovations.
- Economic downturns and healthcare budget constraints could reduce demand for the company's products and services.
- Product recalls and safety concerns could damage the company's reputation and financial performance.
- Fluctuations in currency exchange rates could impact the company's financial results.
What Are the Growth Opportunities for RYLPF?
- Expansion of AI-Driven Diagnostic Solutions: Philips' strategic collaboration with Ibex Medical Analytics to promote digital pathology and AI solutions presents a significant growth opportunity. The market for AI in healthcare diagnostics is projected to reach $3.87 billion by 2026, driven by the increasing need for faster and more accurate diagnoses. By leveraging AI, Philips can enhance its diagnostic imaging capabilities and improve patient outcomes, gaining a competitive edge in the market. Timeline: Ongoing.
- Growth in Connected Care Solutions: The market for connected care solutions, including remote patient monitoring and telehealth, is experiencing rapid growth due to the increasing prevalence of chronic diseases and the growing demand for remote healthcare services. Philips' Connected Care segment, which offers acute patient management and sleep and respiratory care solutions, is well-positioned to capitalize on this trend. The global connected care market is expected to reach $163.2 billion by 2030. Timeline: Ongoing.
- Penetration of Emerging Markets: Emerging markets, such as China and India, represent a significant growth opportunity for Philips due to their large populations and increasing healthcare spending. By expanding its presence in these markets, Philips can tap into new customer segments and drive revenue growth. The healthcare market in emerging economies is projected to grow at a CAGR of 8-10% over the next five years. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: Philips can drive growth through strategic partnerships and acquisitions that expand its product portfolio and geographic reach. By partnering with innovative companies and acquiring complementary businesses, Philips can enhance its competitive position and accelerate its growth trajectory. This includes potential acquisitions in the AI-driven diagnostics and connected care spaces. Timeline: Ongoing.
- Focus on Personal Health Products: The market for personal health products, such as power toothbrushes and infant feeding solutions, is driven by increasing consumer awareness of health and wellness. Philips' Personal Health segment is well-positioned to capitalize on this trend by developing and marketing innovative products that meet consumer needs. The global personal health market is expected to reach $678.5 billion by 2030. Timeline: Ongoing.
What Opportunities Does RYLPF Have?
- Growing demand for telehealth and remote patient monitoring.
- Expansion into emerging markets with increasing healthcare spending.
- Adoption of AI and machine learning in healthcare diagnostics.
- Strategic acquisitions to expand product portfolio.
What Threats Does RYLPF Face?
- Intense competition from established medical device companies.
- Technological obsolescence and disruptive innovations.
- Economic downturns and healthcare budget constraints.
- Fluctuations in currency exchange rates.
What Are RYLPF's Competitive Advantages?
- Strong brand recognition and reputation in the healthcare industry.
- Extensive portfolio of patents and intellectual property.
- Established relationships with hospitals and healthcare providers.
- Global distribution network and service infrastructure.
What Does RYLPF Do?
Koninklijke Philips N.V., founded in 1891 in Amsterdam, Netherlands, has evolved from a lighting manufacturer to a global health technology leader. Initially focused on producing light bulbs, the company expanded into consumer electronics and, more recently, has strategically shifted its focus to healthcare. Today, Philips operates through three primary segments: Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses. The Diagnosis & Treatment segment offers solutions such as MRI, CT, X-ray, and molecular imaging systems, along with related software and services. The Connected Care segment provides acute patient management, emergency care, and sleep and respiratory care solutions. The Personal Health segment focuses on consumer products like power toothbrushes, infant feeding solutions, and male grooming products. Philips has a global presence, serving customers in North America and internationally. Strategic collaborations, such as those with Ibex Medical Analytics and NICO.LAB, enhance its offerings in digital pathology and stroke management, respectively. In May 2013, the company changed its name from Koninklijke Philips Electronics N.V. to Koninklijke Philips N.V., reflecting its strategic focus on health technology.
What Products and Services Does RYLPF Offer?
- Develops and manufactures diagnostic imaging systems, including MRI, CT, and X-ray machines.
- Offers connected care solutions for acute patient management and emergency care.
- Provides sleep and respiratory care devices and services.
- Sells personal health products such as power toothbrushes and infant feeding solutions.
- Offers healthcare informatics and enterprise diagnostic solutions.
- Provides integrated interventional systems for minimally invasive procedures.
- Develops software solutions for diagnostics and intervention.
How Does RYLPF Make Money?
- Sells medical devices and equipment to hospitals, clinics, and healthcare providers.
- Provides recurring revenue through service contracts and software subscriptions.
- Generates revenue from the sale of personal health products to consumers.
- Partners with other companies to expand its product offerings and market reach.
What Industry Does RYLPF Operate In?
Koninklijke Philips N.V. operates in the rapidly evolving health technology industry, driven by increasing demand for advanced diagnostic and treatment solutions, connected care technologies, and personalized health products. The industry is characterized by intense competition, with major players like JDHIF and KONEF vying for market share. Market trends include the growing adoption of AI and machine learning in healthcare, the increasing prevalence of telehealth and remote patient monitoring, and the rising demand for consumer-focused health solutions. Philips is well-positioned to capitalize on these trends, leveraging its technological expertise and established brand reputation.
Who Are RYLPF's Key Customers?
- Hospitals and clinics
- Healthcare providers
- Individual consumers
- Diagnostic centers
- Research institutions
ROE 9%Key Financial Metrics
Return on equity for Koninklijke Philips N.V. stands at 9.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.6%, showing how much profit it generates from its asset base. RYLPF trades at a trailing price-to-earnings ratio of 23.76, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is 8.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.32 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.2%, the inverse of the P/E and a quick read on earnings relative to price.
Koninklijke Philips N.V. (RYLPF) Valuation Context
Valued at $25.24B, RYLPF is classified as a large-cap stock. Relative to its peer group, RYLPF's quantitative score of 44/100 is below the peer average of 60/100.
Company Profile
Koninklijke Philips N.V. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Amsterdam, NL. The company is led by CEO Roy W. O. Jakobs. RYLPF has traded publicly since 2015.
F-Score 8/9Financial Health
Koninklijke Philips N.V.'s Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.03 places it in the grey zone, a middle ground that warrants monitoring.
FY2026 estForward Outlook
Wall Street analysts project Koninklijke Philips N.V. revenue of about $17.84B for fiscal 2026, with EPS near $1.53. The estimate reflects 18 contributing analysts.
RYLPF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Strong brand reputation in healthcare technology.
- Diversified product portfolio across diagnosis, treatment, and personal health.
- Global presence and established distribution network.
- Focus on innovation and strategic partnerships.
Bear Case
- Exposure to regulatory risks and healthcare policy changes.
- Dependence on hospital capital spending cycles.
- Product recalls and safety concerns.
- OTC market trading may limit liquidity.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
RYLPF Latest News
No recent news available for RYLPF.
RYLPF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RYLPF.
Price Targets
Wall Street price target analysis for RYLPF.
RYLPF MoonshotScore
What does this score mean?
The MoonshotScore rates RYLPF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Roy W. O. Jakobs
CEO
Roy Jakobs serves as the CEO of Koninklijke Philips N.V., leading a global workforce of over 67,000 employees. He has a strong background in business management and a proven track record of driving growth and innovation. Prior to becoming CEO, Jakobs held various leadership positions within Philips, including leading the Connected Care businesses. His expertise lies in strategic planning, operational excellence, and customer-centric solutions.
Track Record: Under Roy Jakobs' leadership, Philips has focused on strengthening its position as a health technology leader, driving innovation in diagnostic imaging, connected care, and personal health solutions. He has overseen strategic collaborations to enhance AI-driven diagnostic capabilities and has emphasized the importance of sustainability and social responsibility. He has also focused on improving operational efficiency and streamlining the company's portfolio.
RYLPF OTC Market Information
The OTC Other tier, where RYLPF trades, represents the lowest tier of over-the-counter (OTC) markets. Companies in this tier often have limited or no financial disclosure and may not meet minimum listing requirements of major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries significantly higher risks due to the lack of regulatory oversight and transparency compared to listed companies. Information availability is often scarce, making thorough due diligence crucial.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in RYLPF.
- Lower trading volumes and wider bid-ask spreads can lead to price volatility.
- Lack of regulatory oversight compared to listed companies.
- Potential for fraud or manipulation in the OTC market.
- Difficulty in obtaining reliable information about the company's operations and financial performance.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's potential for future growth and profitability.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Koninklijke Philips N.V. is a well-established company with a long history in the healthcare industry.
- The company has a global presence and a diversified product portfolio.
- Philips has strategic collaborations with reputable organizations.
- The company has a recognized brand name.
- Philips has a history of innovation and technological advancements.
Koninklijke Philips N.V. Healthcare Stock: Key Questions Answered
What does Koninklijke Philips N.V. do?
Koninklijke Philips N.V. is a global health technology company focused on improving people's health and well-being through meaningful innovation. The company operates through three main segments: Diagnosis & Treatment, Connected Care, and Personal Health. Philips develops and manufactures a wide range of medical devices, healthcare solutions, and consumer products, including diagnostic imaging systems, patient monitoring devices, sleep and respiratory care solutions, and personal care appliances. The company's products and services are used by hospitals, clinics, healthcare providers, and consumers worldwide.
What are the main risks for RYLPF?
The main risks for Koninklijke Philips N.V. include regulatory hurdles and healthcare policy changes, intense competition from established medical device companies, economic downturns and healthcare budget constraints, product recalls and safety concerns, and fluctuations in currency exchange rates. As an OTC stock, RYLPF also faces risks associated with limited financial disclosure, lower trading volumes, and a lack of regulatory oversight. Investors should carefully consider these risks before investing in RYLPF.
What are the key factors to evaluate for RYLPF?
Koninklijke Philips N.V. (RYLPF) holds an AI score of 44/100 (low). Not financial advice.
How frequently does RYLPF data refresh on this page?
RYLPF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven RYLPF's recent stock price performance?
Koninklijke Philips N.V. (RYLPF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong brand reputation in healthcare technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RYLPF overvalued or undervalued right now?
Valuing Koninklijke Philips N.V. (RYLPF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying RYLPF?
Before investing in Koninklijke Philips N.V. (RYLPF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding RYLPF to a portfolio?
Key strength of Koninklijke Philips N.V. (RYLPF): Strong brand reputation in healthcare technology. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for RYLPF, limiting the depth of some sections.
- OTC market data may be less reliable than data for listed companies.